SOTIO Biotech

It’s #NationalInternDay in the U.S., and we are grateful to the interns who have contributed to our work at SOTIO. This summer, through the Erasmus Plus program, we’ve had the pleasure of hosting a group of talented interns from universities across the EU, including Medical University of Vienna, IMC Krems University of Applied Sciences and Sorbonne Université. Thank you to our senior scientist, Jitka Fucikova, for leading these students. We appreciate their contributions to our work to develop next-generation immunotherapies. #ErasmusPlus #studyabroad #internship #jsmePPF

Today we announced a research collaboration and exclusive licensing agreement with Biocytogen to expand our antibody-drug conjugate pipeline. This agreement enables us to license multiple fully human bispecific antibodies generated with Biocytogen’s RenLite® platform for developing next-generation ADCs targeting solid #tumors. Read more in our press release: https://lnkd.in/eYvKfxub #biotechnology #ADCs #CancerTherapy #jsmePPF

Our director of pharmacology, Irena Adkins, spoke about her work at SOTIO and her love of science with EDUCA Magazín, a prestigious Czech magazine focused on education. She shares the surprises and satisfactions that come from a scientific career, and why she was ultimately drawn to apply her expertise to develop new medicines for cancer. Check out the English translation of the interview here: https://bit.ly/4chAlfe #biotechnology #careeradvice #WomeninSTEM #jsmePPF

Sarcoma is a rare type of cancer that develops in the bones or soft tissues. For patients with advanced, unresectable, or metastatic sarcoma, treatment options are generally limited. In our ongoing DUET-01 clinical trial we are studying the use of BOXR1030, our enhanced CAR T-cell therapy, in patients with #sarcoma and other solid tumor types in need of new treatment options. More on our website: https://lnkd.in/ePiRakUd #SarcomaAwarenessMonth #biotechnology #cancer #oncology

This month, we have initiated two new sites for our ongoing DUET-01 clinical trial in London, UK, at the University College London Hospitals NHS Foundation Trust and The Royal Marsden NHS Foundation Trust. This study marks the first-in-human study of BOXR1030, an advanced CAR T-cell therapy engineered to enhance proliferation in the solid tumor microenvironment more effectively than standard CAR T therapies. Learn more about this novel therapy in our recent press release: https://bit.ly/4b65h0l #biotechnology #immunotherapy #cancer #jsmePPF

This week we reunited with employees from both our U.S. and European offices for our annual SOTIO & SCTbio Day, a time to recognize the progress we have made this year as a team and spend time outside with our colleagues. At Letnany Airport Prague we participated in various activities together, such as air racing, moving the statue, assembling plane parts, team swing and many others. #biotechnology #jsmePPF 

Last month marked our team’s seventh year participating in the “Do práce na kole” (#BiketoWork) challenge in #Prague, where many of our colleagues are based, alongside our sister company, SCTbio. Together, the SOTIO and SCTbio teams traveled 4684 km (2910 miles) and saved 1150 kg (2535 pounds) of CO2, aiming to help create a greener and healthier environment. The winning team includes Christian Frantz, Anežka Kopecká, Alice Majetičová, Monika Janičíková and Pavlína Šestáková. Individual winners include Anežka Kopecká at 339 km (211 miles) and Christian Frantz at 1053 km (654 miles.) Congrats, team! #Environment #Sustainability #dopracenakole #jsmePPF

Immuno-oncology – activating the immune system to fight #cancer – has been revolutionary for treating blood cancer. However most solid tumors still lack effective #immunotherapy. SOTIO is focused on developing new treatments for solid tumors, with 3 programs in clinical trials. #Immune2Cancer #CancerResearch #biotechnology #jsmePPF

Over the weekend at American Society of Clinical Oncology (ASCO) Annual Meeting we presented a trial-in-progress poster on our DUET-01 Phase 1/2 study of BOXR1030, a metabolically enhanced CAR T-cell therapy for the treatment of #solidtumors. The poster was presented by Ecaterina Dumbrava from MD Anderson Cancer Center and Pauline Gerard Duhard from SOTIO. View the poster here: https://lnkd.in/eMBun6PA #ASCO2024 #biotechnology #CancerResearch

We are looking forward to attending #BIO2024 next week to reconnect with peers and colleagues and share the latest on our programs across antibody-drug conjugates, immunocytokines and our next-generation BOXR CAR-T. #immunotherapy #biotechnology #ADCs #jsmePPF